Patents Assigned to OLATEC THERAPEUTICS LLC
-
Patent number: 11576888Abstract: The present invention is directed to a method for treating cardiovascular diseases such as acute myocardial infarction, atherosclerosis, heart failure, stroke, thrombosis, carditis (including acute myocarditis, acute pericarditis and complicated pericarditis), cardiac allograft rejection, cardiomyopathy, and peripheral vascular diseases. The method comprises administering to a subject in need thereof dapansutrile, in an effective amount. A preferred route of administration is oral administration.Type: GrantFiled: June 25, 2019Date of Patent: February 14, 2023Assignee: OLATEC THERAPEUTICS LLCInventors: Carlo Marchetti, Charles A. Dinarello
-
Patent number: 11517554Abstract: The present invention is directed to a method for preventing and/or treating Alzheimer's disease. The method comprises administering to a subject in need thereof an effective amount of dapansutrile. The method reduces neuroinflammation and improves the cognitive functions such as learning and memory processes of the subject. Dapansutrile can be administered to the subject orally at a dose of 100-2000 mg/day for 3 months to 5 years or longer.Type: GrantFiled: July 29, 2020Date of Patent: December 6, 2022Assignee: OLATEC THERAPEUTICS LLCInventor: Charles A. Dinarello
-
Patent number: 10548870Abstract: The present invention is directed to a method for treating multiple sclerosis by administering dapansutrile to a subject in need thereof. A preferred route of administration is oral administration.Type: GrantFiled: July 1, 2019Date of Patent: February 4, 2020Assignee: OLATEC THERAPEUTICS LLCInventor: Charles A. Dinarello
-
Patent number: 10143675Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ?-(methylthio)alkylnitriles such as 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.Type: GrantFiled: October 21, 2016Date of Patent: December 4, 2018Assignee: OLATEC THERAPEUTICS LLCInventors: Joseph P. St. Laurent, Gerald S. Jones, David M. Bresse
-
Patent number: 9889111Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a ?-(arylsulfonyl)alkylnitrile compound, or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering an ?-(arylsulfonyl)alkylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.Type: GrantFiled: October 31, 2016Date of Patent: February 13, 2018Assignee: OLATEC THERAPEUTICS LLCInventors: Joseph St. Laurent, Gerald S. Jones, David M. Bresse
-
Patent number: 9815781Abstract: The present invention relates to processes for preparing for preparing 3-(methylsulfonyl)propionitrile. The processes comprise the steps of first reacting 2-chloroethyl methyl sulfide with sodium cyanide or potassium cyanide in a solvent or a solvent mixture to form 3-(methylthio)propionitrile, and then reacting the isolated 3-(methylthio)propionitrile with acetic anhydride, acetic acid, and hydrogen peroxide to form 3-(methylsulfonyl)propionitrile.Type: GrantFiled: February 17, 2016Date of Patent: November 14, 2017Assignee: OLATEC THERAPEUTICS LLCInventors: Gerald S. Jones, Scott A. Goodrich
-
Patent number: 9770428Abstract: The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.Type: GrantFiled: November 11, 2016Date of Patent: September 26, 2017Assignee: OLATEC THERAPEUTICS LLCInventor: Joseph St. Laurent
-
Patent number: 9770429Abstract: The present invention is directed to a method of treating an inflammatory skin disease or disorder, such as dermatitis, psoriasis, acne, or rosacea. The method comprises administering to the subject 4-methylsulfonyl-2-butenenitrile, in an amount effective to reduce or eliminate the symptoms of the inflammatory skin disease or disorder. Topical administration and oral administration are preferred routes of administration.Type: GrantFiled: December 15, 2016Date of Patent: September 26, 2017Assignee: OLATEC THERAPEUTICS LLCInventors: Joseph P. St. Laurent, Gerald S. Jones, David M. Bresse, Scott A. Goodrich
-
Patent number: 9492420Abstract: The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.Type: GrantFiled: March 5, 2015Date of Patent: November 15, 2016Assignee: OLATEC THERAPEUTICS LLCInventor: Joseph St. Laurent
-
Patent number: 9481644Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a ?-(arylsulfonyl)alkylnitrile compound, or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering an ?-(arylsulfonyl)alkylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.Type: GrantFiled: November 26, 2014Date of Patent: November 1, 2016Assignee: OLATEC THERAPEUTICS LLCInventors: Joseph St. Laurent, Gerald S. Jones, David M. Bresse
-
Patent number: 9474734Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ?-(methylthio)alkylnitriles such as 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.Type: GrantFiled: August 21, 2015Date of Patent: October 25, 2016Assignee: OLATEC THERAPEUTICS LLCInventors: Joseph P. St. Laurent, Gerald S. Jones, David M. Bresse
-
Patent number: 9440916Abstract: The present invention is directed to a method of treating an inflammatory skin disease or disorder, such as dermatitis, psoriasis, acne, or rosacea. The method comprises administering to the subject 3, 4-bis-benzylsulfonylbutyronitrile in an amount effective to reduce or eliminate the symptoms of the inflammatory skin disease or disorder. Topical administration and oral administration are preferred route of administration.Type: GrantFiled: March 23, 2016Date of Patent: September 13, 2016Assignee: OLATEC THERAPEUTICS LLCInventors: Joseph P. St. Laurent, Gerald S. Jones, David M. Bresse, Scott A. Goodrich
-
Patent number: 9439880Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.Type: GrantFiled: December 3, 2015Date of Patent: September 13, 2016Assignee: OLATEC THERAPEUTICS LLCInventors: Joseph P. St. Laurent, Gerald S. Jones, David M. Breese
-
Patent number: 9399620Abstract: The present invention relates to processes for preparing 3-methylsulfonylpropionitrile. The processes provide a good yield and a good purity of the final product and provide a controllable reaction. The present invention also relates to a crystalline form of 3-methylsulfonylpropionitrile having X-ray diffraction peaks at 13.9±0.1, 19.2±0.1, 20.0±0.1, 22.5±0.1, 23.2±0.1, 25.7±0.1, 28.1±0.1, 29.9±0.1, and 30.6±0.1 degrees 2?, and wherein the most intense peak is the peak at 13.9±0.1 degrees 2?.Type: GrantFiled: April 29, 2015Date of Patent: July 26, 2016Assignee: OLATEC THERAPEUTICS LLCInventors: Joseph P. St. Laurent, Gerald S. Jones, David M. Bresse